99mTc-labeled boronic acid derivatives for SPECT myocardial perfusion imaging: Improved version 2.0

Excerpt

According to several observers, the late 1980s and early 1990s are considered to be the « golden age » of nuclear cardiology, regarding the myocardial perfusion imaging (MPI) field with Single Photon Emission Computed Tomography (SPECT). Effectively, within a few years, three differents 99mTc-labeled MPI agents have been approved by the Food and Drug Administration (FDA) for clinical use : 99mTc-sestamibi, 99mTc-teboroxime and 99mTc-tetrofosmin.1‐4 In the early 1990s several others 99mTc-MPI agents have been the subjects of basic, animal and clinical researches such as 99mTc-Furifosmin and 99mTc-N-NOEt.5,6 However, these two agents have not been approved. At the same time, PET myocardial perfusion tracers started to be progressively introduced in clinical practice. Although during the last 30 years several studies have been performed in order to synthesize new SPECT MPI agents, no significant potential radiotracer has emerged, so that 99mTc-sestamibi and 99mTc-Tetrofosmin are still used in almost every SPECT MPI clinical studies around the world, with the exception of 201Thallium for more specific indications. …